Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic testing and precision medicine, announced that a MyRisk ® Hereditary Cancer Test with RiskScore ® study has been named in the ...
Agreement Reached on Primary Endpoint and Phase 3 Trial Design. Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering. FARMINGTON HILLS, Mich., Dec. 19, 2024 (GLOBE ...
This article explores the latest developments in the life insurance sector, examines factors influencing premium rates, and highlights the role of term insurance in providing cost-effective coverage.